Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Grifols SA ( (GRFS) ).
Grifols reported its full-year 2025 results on February 26, 2026, posting revenues of €7.52 billion, up 7.0% at constant currency, largely driven by robust Biopharma growth and strong demand for immunoglobulins. Adjusted EBITDA rose to €1.83 billion with an improved margin, while net profit more than doubled to €402 million and free cash flow before M&A climbed to €468 million, helping reduce leverage from 4.6x to 4.2x and supporting a series of credit rating upgrades.
The company highlighted structural improvements in cash generation, a focus on deleveraging and plans to refinance 2027 debt in two stages, starting in the first half of 2026. Regulatory wins, including EMA approval for Egypt-sourced plasma and EMA/FDA approvals for new fibrinogen products PRUFIBRY and FESILTY, together with launches in Europe and expected U.S. rollout in Q2 2026, are set to strengthen Grifols’ product portfolio and long-term positioning in plasma therapies despite pricing pressure in China for albumin.
The most recent analyst rating on (GRFS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Outperform.
Grifols SA’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. While technical indicators suggest potential bearish momentum, the company’s robust revenue growth and operational efficiency provide a solid foundation. Valuation is moderate, offering neither a significant discount nor premium.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols SA is a global healthcare company based in Barcelona and a leading producer of plasma-derived medicines, with a strong focus on its Biopharma business and key immunoglobulin, albumin, and alpha-1 franchises. The company also operates a diagnostics division and is building self-sufficiency plasma platforms in Egypt and Canada to reinforce supply security and its competitive positioning in major markets such as the U.S. and China.
Average Trading Volume: 495,742
Technical Sentiment Signal: Hold
Current Market Cap: $7.81B
Find detailed analytics on GRFS stock on TipRanks’ Stock Analysis page.